Education
About Us
Working with TipRanks
Follow Us
Arcutis Biotherapeutics (ARQT)
NASDAQ:ARQT
ARQT Stock Chart & Stats
Day’s Range― - ―
52-Week Range$6.99 - $17.75
Previous CloseN/A
Volume446.87K
Average Volume (3M)2.73M
Market Cap
$1.64B
Enterprise Value$1.62B
Total Cash (Recent Filing)-$3.42M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.44
Next Earnings
May 06, 2025EPS Estimate
-0.21Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.16
Shares Outstanding118,638,240
10 Day Avg. Volume2,654,095
30 Day Avg. Volume2,732,979
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)10.27
Price to Cash Flow (P/CF)-674.50
P/FCF Ratio0.00
Enterprise Value/Market Cap0.99
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit9.14
Enterprise Value/Ebitda-14.80
Forecast
1Y Price Target
$19.00Price Target Upside31.49% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
---
Arcutis Biotherapeutics News
PremiumCompany Announcements
Arcutis Biotherapeutics Appoints New Chief Financial Officer
---
Bulls Say, Bears Say
Bulls Say
Financial PerformanceArcutis anticipates continuing its sales growth momentum into 2025, building on a transformational 2024.
Patent LitigationThe joint stipulation agreement between Arcutis and Padagis to ongoing patent litigation is seen as a win for Arcutis, providing confidence about the company's runway of exclusivity.
Strategic ValuePatent protection for Zoryve cream 0.3% extends until at least 2037, enhancing the strategic value of Arcutis shares.
Bears Say
Commercial RisksKey risks include commercial success is not assured since dermatology remains a highly competitive segment, and product concentration risk since Zoryve is the company's only commercial asset.
Generic CompetitionOngoing litigation has weighed on Arcutis shares, affecting the company's trading in-line with Zoryve's commercial performance.
Sales EstimatesQuarter one seasonality is impacting sales estimates, contributing to decreased quarterly sales projections.
---
Ownership Overview
7.85% Insiders
17.94% Mutual Funds
0.32% Other Institutional Investors
60.33% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ARQT FAQ
What was Arcutis Biotherapeutics’s price range in the past 12 months?
Arcutis Biotherapeutics lowest stock price was $6.99 and its highest was $17.75 in the past 12 months.
What is Arcutis Biotherapeutics’s market cap?
Arcutis Biotherapeutics’s market cap is $1.64B.
When is Arcutis Biotherapeutics’s upcoming earnings report date?
Arcutis Biotherapeutics’s upcoming earnings report date is May 06, 2025 which is in 11 days.
How were Arcutis Biotherapeutics’s earnings last quarter?
Arcutis Biotherapeutics released its earnings results on Feb 25, 2025. The company reported -$0.09 earnings per share for the quarter, beating the consensus estimate of -$0.255 by $0.165.
Is Arcutis Biotherapeutics overvalued?
According to Wall Street analysts Arcutis Biotherapeutics’s price is currently Undervalued.
Does Arcutis Biotherapeutics pay dividends?
Arcutis Biotherapeutics does not currently pay dividends.
What is Arcutis Biotherapeutics’s EPS estimate?
Arcutis Biotherapeutics’s EPS estimate is -0.21.
How many shares outstanding does Arcutis Biotherapeutics have?
Arcutis Biotherapeutics has 118,638,240 shares outstanding.
What happened to Arcutis Biotherapeutics’s price movement after its last earnings report?
Arcutis Biotherapeutics reported an EPS of -$0.09 in its last earnings report, beating expectations of -$0.255. Following the earnings report the stock price went up 8.361%.
Which hedge fund is a major shareholder of Arcutis Biotherapeutics?
Currently, no hedge funds are holding shares in ARQT
---
Arcutis Biotherapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$19.00 (31.49% Upside)
$19.00 (31.49% Upside)
Blogger Sentiment
Bullish
ARQT Sentiment 88%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 54.2K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $1.2M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 0.6%
Last 30 Days ▲ 22.4%
Last 30 Days ▲ 22.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
65.33%
12-Months-Change
Fundamentals
Return on Equity
-113.76%
Trailing 12-Months
Asset Growth
2.20%
Trailing 12-Months
Company Description
Arcutis Biotherapeutics
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical foam formulation of roflumilast for the treatment of seborrheic dermatitis and scalp psoriasis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; and ARQ-255, a topical formulation of ARQ-252 designed to reach deeper into the skin in order to treat alopecia areata. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.
---
ARQT Company Deck
---
ARQT Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call reflected a strong performance driven by significant revenue growth, successful product launches, and expanded Medicaid coverage. However, challenges such as Q1 revenue fluctuations, Medicare Part D negotiations, and minimal contribution from the Kowa partnership were noted. The sentiment is balanced with optimism for future growth.Read More>---
ARQT Stock 12 Month Forecast
Average Price Target
$19.00
▲(31.49% Upside)
Technical Analysis
Denali Therapeutics
―
Harmony Biosciences Holdings
―
Immunocore Holdings
―
NewAmsterdam Pharma Company
―
Recursion Pharmaceuticals
―
Best Analysts Covering ARQT
1 Year
1 Year Success Rate
9/18 ratings generated profit
1 Year Average Return
+33.21%
reiterated a buy rating 17 days ago
Copying Serge Belanger's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of +33.21% per trade.
---